In this one-hour webinar, sleep physician-presenters explore how to better identify, assess, and manage residual EDS in 2026—moving beyond the AHI to focus on real-world functional outcomes, patient-reported symptoms, and emerging treatment strategies.
Q3 results highlight increased Sunosi prescriptions and advancements in Axsome’s late-stage trials for narcolepsy and shift work disorder.
Axsome Therapeutics reported third-quarter business updates, noting a continued increase in prescriptions for Sunosi and clinical trial progress.
Read More
In a small clinical trial, solriamfetol—approved for treating excessive daytime sleepiness caused by narcolepsy or obstructive sleep apnea—was an effective therapy for attention-deficit/hyperactivity disorder in adults.
Read More
One poster will feature results from the SHARP study, a trial of Sunosi in 59 patients with excessive daytime sleepiness associated with OSA and impaired cognitive function.
Read More
In its Q2 business highlights, Axsome Therapeutics provided updates on a new potential indication for solriamfetol for shift work disorder, announced progress for its narcolepsy drug candidate, and revealed positive results from the relaunch of Sunosi.
Read More
The presentations include data from the SHARP study in patients with excessive daytime sleepiness associated with OSA, real-world data from OSA patients taking Sunosi as part of the SURWEY study in Germany, healthcare resource use in OSA patients with residual EDS, and effect sizes and numbers needed to treat analyses.
Read More
Axsome Therapeutics will present data on Sunosi, including results from the SHARP study, at the American Society of Clinical Psychopharmacology Annual Meeting, being held May 30 to June 3.
Read More
Axsome Therapeutics reported first-quarter corporate updates, noting a growing patient base for Sunosi and progress for its narcolepsy drug candidate AXS-12.
Read More
Solriamfetol is being trialed in 59 patients with excessive daytime sleepiness associated with obstructive sleep apnea and impaired cognitive function.
Read More
Axsome Therapeutics discusses what’s next for Sunosi, used to reduce excessive daytime sleepiness in adults with narcolepsy or sleep apnea, and AXS-12, a narcolepsy drug candidate in clinical trials.
Read More
The license agreement will expand the availability of Sunosi, a medicine used to reduce excessive daytime sleepiness in adults with narcolepsy or OSA, across Europe and MENA.
Read More
New research looked at whether a history of depression changed outcomes in patients with sleep apnea or narcolepsy who use solriamfetol to control excessive daytime sleepiness.
Read More